Effectiveness of biologic switching in a real-life, Belgian severe asthma cohort

Immun Inflamm Dis. 2024 Oct;12(10):e70023. doi: 10.1002/iid3.70023.

Authors

Lucie Lafarge¹, Charles Pilette^{1

2}, Céline Bugli³, Antoine Froidure^{1

2}

Affiliations

¹ Pneumology Department, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.
² Pole of Pulmonology, ENT and skin (LUNS Lab), Institut de Recherche Expérimentale et Clinique, UCLouvain, Louvain-la-Neuve, Walloon Brabant, Belgium.
³ Support en Méthodologie et Calcul Statistique (SMCS), Université catholique de Louvain, Brussels, Belgium.

Abstract

In this observational study, we show that switching biologics in severe asthma results in a high proportion of controlled patients.

© 2024 The Author(s). Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.

Publication types

Observational Study

MeSH terms

Adult
Aged
Anti-Asthmatic Agents* / administration & dosage
Anti-Asthmatic Agents* / therapeutic use
Asthma* / drug therapy
Asthma* / epidemiology
Belgium / epidemiology
Biological Products / therapeutic use
Cohort Studies
Drug Substitution
Female
Humans
Male
Middle Aged
Severity of Illness Index
Treatment Outcome

Substances

Anti-Asthmatic Agents
Biological Products